A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions

Advanced Solid Malignancies

Interventions

DRUG

Fluzoparib

Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.

Trial Locations (2)

No.307 Hospital, Academy of Military Medical Sciences, Beijing

Beijing Cancer Hospital, Beijing

All Listed Sponsors

collaborator

307 Hospital of PLA

OTHER

collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02575651 - A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter